// App-Quantinova.ai

3089 : Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Researchers

Presenter

  • Srdan Verstovsek

Principal Investigators

  • Shreekant Parasuraman

  • Jingbo Yu

  • Anne Shah

  • Shambhavi Kumar

  • Ann Xi

  • Claire Harrison

Medical Centers

  • The University of Texas MD Anderson Cancer Center, Leukemia Department, Houston, TX

  • Incyte Corporation, Wilmington, DE

  • Avalere Health LLC, Washington, DC

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Hematological malignancies

  • Multiple Myeloma

  • Myelofibrosis

  • Solid malignancies

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved